



**All India Institute of Medical Sciences, Bhubaneswar**  
**At - Sijua (Patrapada), Post - Dumuduma, Bhubaneswar (Odisha) - 751019**

To be uploaded in website: [www.aiimsbhubaneswar.nic.in](http://www.aiimsbhubaneswar.nic.in) (e-tender)

Reference No: STORE- 76/135/2025-STPUR SEC/29

Dated: 22/09/2025  
23/09/2025

**Sub: Procurement of 72 vials of Inj. NIVOLUMAB-40 mg. for the external project " Safety and Efficacy of addition of nivolumab to ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced stage pediatric Hodgkin Lymphoma: A Phase II/III, multicentric, open label, randomized controlled trial" under PI- Dr. Debasish Sahoo Dept. of Medical Oncology, AIIMS, Bhubaneswar.**

**INVITING COMMENTS THEREON**

Department of Medical Oncology/Hematology at AIIMS, Bhubaneswar has requested for Procurement of Inj. NIVOLUMAB - 40 mg, from M/s Bristol Myers Squibb India Private Limited, through their Authorized Distributors M/s Friends Specialty Medicine Pvt Ltd.

The Notice is being uploaded for general information of prospective manufacturer/Authorized Distributors/Dealers to submit their objection/proposal/comments, if any, on proprietorship of the above items.

In case the product of any manufacturer/Authorized distributor/Dealer conforms to the enclosed specifications, they may submit their proposal for the supply of the same along with the brochures, point by point compliance of the enclosed specifications along with all documentary evidence. One quotation of the product may also be submitted.

The objections/comments/proposal should be sent in sealed cover to the Office of Sr. Procurement Cum Stores Officer, AIIMS, Bhubaneswar (Odisha) – 751019 or through E-mail to [sp\\_helpdesk@aiimsbhubaneswar.edu.in](mailto:sp_helpdesk@aiimsbhubaneswar.edu.in) so as to reach on or before **date: 08-10-2025** failing which it will be presumed that no other firm is interested to offer comments/protest/object and case will be decided on its merits.

The Ref. no. – **STORE- 76/135/2025-STPUR SEC** Dated: 23-09-2025, due on dated: 08-10-2025 should be superscripted on sealed envelope.

**Enclosures:**

1. User Proprietary Article Certificate of AIIMS, Bhubaneswar
2. PAC of M/s Bristol Myers Squibb Company.
3. OEM Authorisation Certificate of supplier - (M/s Friends Specialty Medicine Pvt Ltd)
4. Budgetary Quotation

Digitally signed by  
**KUNAL CHAKRABORTY**  
Date: 22-09-2025

Sr. Procurement Cum-Store Officer (I/c)  
AIIMS, Bhubaneswar

Ph.: 0674-2476035/669/044

Email: [spo@aiimsbhubaneswar.edu.in](mailto:spo@aiimsbhubaneswar.edu.in)

**Copy to:**

1. PI, Medical Oncology/Hematology
2. Accounts Officer
3. Help Desk, S&P

: for information please  
: for information please  
: for information & necessary  
action please.

**AIIMS, BHUBANESWAR****Proprietary Article Certificate  
Valid for the Current Financial Year**

File No. and Date Reference :		
1	Description of article	Nivolumab is a new targeted therapy used in many malignancies, either as single agent or in combination with other chemotherapeutic drugs.
2	Forecast of quantity /annual requirement	72 vials
3	Approximate estimated value for above quantity	Rs. 24,49,440/-
4	Maker's name and address	Bristol Myers Squibb India Pvt Ltd
5	Name(s) of authorized dealers/ stockists	Friends Speciality Medicine Pvt Ltd 1st Floor, Ward No.33, 83/1, Dr. Suresh Chandra Banerjee Road Beliaghata, Kolkata Pin -700010
6	I approve the above purchase on PAC basis and certify that : - Note- Tick to retain only one out of (b), C-1) or (c-2) whichever is applicable and cross out others. Please do confirm (a) by ticking it - without which PAC certificate will be invalid.	
6 (a)	This is the only firm who is manufacturing / stocking this item. AND	YES
6 (b)	A Similar article is not manufactured / sold by any other firm, which could be used in lieu OR	YES
6 (c-1)	No other make/brand will be suitable for following tangible reasons (like OEM/ Warranty, spares.) : OR	NO
6 (c)	No other make/brand will be suitable for following intangible reasons (if PAC was also given in the last procurement cycle, please also bring out efforts made since then to locate more sources) : OR	NO
7	Reference of concurrence of finance wing to the proposal :	ICMR- NCG funded study; budget approved for the study
History of PAC Purchase of this item for past three years may be given below :		NA
Name of the Supplier		
Order/ Tender Reference & Date	Quantity Ordered	Basic Rate on Order (Rs.)
		Adverse Performance Reported if Any

Signature of Approving Authority.....

Date..... Designation of Officer.....

Dr. Ashutosh Biswas  
कार्यकारी निदेशक / Executive Director  
एम्स, भुवनेश्वर  
AIIMS, Bhubaneswar-751019

Signature of the Identifying Officer  
Dr. Debajit Sahoo  
Asst. Professor  
Dept. of Medical Oncology/Hematology  
Regd. No.-DMC-80430  
AIIMS Bhubaneswar-751019



BMS Ref: BMS\_KAM\_1400

Date: 07<sup>th</sup> August 2025

To,  
The Assistant Professor,  
Department of Medical Oncology/ Haematology,  
AIIMS, Bhubaneswar.

Sub.: Authorization Letter.

Dear Sir,

We hereby authorize the following mentioned stockiest as our authorized suppliers to your institution which is valid up to **31<sup>st</sup> March 2026**.

Friends Speciality Medicine Pvt Ltd  
1st Floor, Ward No.33, 83/1,  
Dr. Suresh Chandra Banerjee Road  
Beliaghata, Kolkata  
Pin -700010

Contact Person: ~~Nimai~~ Charan Maity  
Mob: 9312331380 / 8443902900  
Email-kolkata@fsmpl.co.in, sunil@fsmpl.co.in.  
GST No: 19AADCF5604M1ZE

They have been authorized to collect orders, effect supplies, raise bills and receive payments on our behalf to your institution.

However, the right to terminate this authorization at any point of time within the validity period will remain with the company.

Thanking you,

Yours faithfully,  
For M/s Bristol Myers Squibb India Private Limited,

Karan Sharma  
Associate Director: Business Strategy & Operations, India  
Email Id: tenders.india@bms.com





### Proprietary Article Certificate

Date: October 12, 2023

#### TO WHOMSOEVER IT MAY CONCERN

This is to certify that Nivolumab (Opdyta®) 10 mg/mL concentrate for solution for infusion: 40 mg and 100 mg is a proprietary product of Bristol-Myers Squibb Company; and Bristol-Myers Squibb India Private Limited, Mumbai is the sole importer and marketer of the drug in India.

Nivolumab (Opdyta®) 10 mg/mL concentrate for solution for infusion: 40 mg and 100 mg is

**Manufactured by:**

Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company, Road 686 Km 2.3 Bo. Tierras Nuevas Manati, Puerto Rico 00674 (United States)

**Batch release by:**

Swords Laboratories Unlimited Company t/a, Bristol-Myers Squibb Cruiserath Biologics, Cruiserath Road, Mulhuddart, Dublin 15, D15 H6EF, Ireland

**Imported by:** Bristol-Myers Squibb India Private Limited, Bldg. B-4, Gala No. 3B & 4B, Citylink Warehousing Complex Mumbai Nashik Highway, Vadape Village, Bhiwandi-16 (Thane Z5), Bhiwandi, Maharashtra (India) - 421302.

**Marketed By:** Bristol-Myers Squibb India Private Limited, One International Center, 6th Floor, Tower 1 Senapati Bapat Marg, Elphinstone (W) Mumbai 400 013, India

This certificate is valid for a period of two years from the date of issue.

T. Ben David Oct 12, 2023


Talia Ben David

Director – Global Regulatory Collaboration & Service Center

State of FL County of Hillsborough  
Subscribed and sworn to (or affirmed) before me on this  
12 day of October, 2023 by  
Talia Ben David proved to me on the basis  
of satisfactory evidence to be the person (s) who appeared before me.

Notary Signature

Personally Known







BMS Ref: BMS\_KAM\_1400

Date: 07<sup>th</sup> August 2025

To,  
The Assistant Professor,  
Department of Medical Oncology/ Haematology,  
AIIMS, Bhubaneswar.

Sub.: Rates Quotation.

Dear Sir,

We are pleased to enclose herewith our **rates quotation** valid up to **31<sup>st</sup> March 2026**.

Sl. No	Generic Name	Brand Name	Pack Size	Hospital Price (Excluding GST)	MRP (Including GST)	GST %	HSN Code
1	Inj. Nivolumab 40mg	Opdyta 40 mg	1 Vial	32,400.00	43,780.00	5%	30021500

GST will be charged as applicable and as in force on the date of supply, as per govt.'s rules and regulations.

The Above-mentioned product is our original research product having valid PAC.

We hereby undertake that rate quoted above are the same rates, offered to any other Government Hospitals/Institutions.

We look forward to your valued order.

Thanking you,

Yours faithfully,  
For M/s Bristol Myers Squibb India Private Limited,

Karan Sharma  
Associate Director: Business Strategy & Operations, India  
Email Id: tenders.india@bms.com

*Debauch Sehra*